AvKARE Initiates Nationwide Recall of Carboxymethylcellulose Sodium Ophthalmic Solution Due to Label Mix-Up
AvKARE has initiated a Class III recall (D-0175-2025) for 16,677 cartons of Carboxymethylcellulose Sodium Ophthalmic Solution 0.5% due to a label mix-up. This voluntary action, stemming from their Pulaski, TN facility, highlights persistent quality control challenges at AvKARE, impacting supply chain reliability and demanding immediate risk assessment from procurement and regulatory teams.
FDA-Initiated Recall: Label Mix-Up Impacts Carboxymethylcellulose Sodium Ophthalmic Solution
On December 18, 2024, the U.S. Food and Drug Administration (FDA) announced a Class III voluntary recall, D-0175-2025, initiated by AvKARE for its Carboxymethylcellulose Sodium Ophthalmic Solution 0.5% Moisturizing Lubricant Eye Drops. This recall, classified as Class III, was prompted by a significant label mix-up, indicating a fundamental breakdown in quality control processes. The affected product, packaged in 0.5 FL OZ (15 mL) bottles, carries NDC 50268-068-15 and specifically pertains to Lot #: 0160, with an expiration date of April 26, 2026. A total of 16,677 cartons of this ophthalmic solution were distributed nationwide within the United States. For procurement directors and supply chain VPs, this event necessitates an immediate review of inventory and distribution channels for Carboxymethylcellulose Sodium Ophthalmic Solution. The label mix-up, while classified as Class III (meaning use is not likely to cause adverse health consequences), still poses a risk of patient confusion and potential inappropriate use, which can lead to brand erosion and increased customer service inquiries. Regulatory affairs heads must evaluate the implications for product integrity and compliance, particularly concerning labeling accuracy and Good Manufacturing Practices (GMP) adherence. Business development executives should note the potential for market disruption and assess the competitive landscape for alternative suppliers of similar ophthalmic products.
AvKARE's Operational Footprint and Diverse Product Portfolio
AvKARE, identified as the recalling firm, operates from Pulaski, Tennessee, in the United States. While the specific facility involved in this labeling error is not detailed beyond the company's primary location, AvKARE is known as a manufacturer with a broad portfolio of pharmaceutical products. This recall of an over-the-counter (OTC) ophthalmic solution, Carboxymethylcellulose Sodium, adds to their regulatory challenges. AvKARE's product range extends across various therapeutic areas, including Central Nervous System (e.g., Pregabalin, Mirtazapine, Lamotrigine, Trazodone Hydrochloride), Cardiovascular (e.g., Nebivolol, Cilostazol, Verapamil), Oncology & Immunology (e.g., Abiraterone, Anastrozole, Dasatinib), and Anti-Infectives (e.g., Chloroquine Phosphate, Azithromycin, Oseltamivir). This wide array of products means that quality control issues, such as the current label mix-up, can have far-reaching implications across multiple drug classes and patient populations. Procurement and supply chain leaders sourcing any of AvKARE's diverse molecules, including Dutasteride, Cinacalcet, or Sildenafil, should consider this event within the context of the company's overall quality systems and potential for broader supply disruptions.
Supply Chain Exposure: Nationwide Distribution and Commercial Impact
The recalled Carboxymethylcellulose Sodium Ophthalmic Solution was distributed nationwide across the United States. This broad distribution pattern means that the recall has a significant footprint, impacting a wide network of pharmacies, distributors, and potentially healthcare providers. For supply chain VPs and procurement directors, this necessitates a comprehensive and rapid response to identify and quarantine affected product lots (Lot #: 0160, Exp. Date April 26, 2026) throughout their entire distribution network. The quantity of 16,677 cartons represents a substantial volume, requiring considerable logistical effort for retrieval and reconciliation. Commercially, this recall can lead to several adverse outcomes. Distributors and retailers face the operational burden of managing returns and potential financial losses from unsaleable product. Furthermore, the incident can erode consumer trust in the brand and, by extension, in the retailers carrying the product. Regulatory affairs teams must ensure that all downstream partners are adequately informed and compliant with recall procedures, including proper communication to consumers. Business development executives should assess how this event might open opportunities for competitors to gain market share in the ophthalmic solution segment, especially if AvKARE's remediation efforts are perceived as slow or insufficient.
Identifying Alternative Suppliers for Ophthalmic Solutions and Related APIs
Given AvKARE's recurring regulatory challenges, procurement teams should proactively identify and qualify alternative suppliers for Carboxymethylcellulose Sodium Ophthalmic Solution and other critical products sourced from AvKARE. Diversifying the supplier base is a crucial strategy to mitigate supply chain risks and ensure continuity of supply. Potential alternative suppliers for various pharmaceutical products, as identified in our intelligence, include Aurohealth, Granules India (based in India), NorthStar Rx, NURAY CHEMICALS, Indoco Remedies, Armas Pharmaceuticals (based in India), Societal CDMO Gainesville, and Apotex (based in Canada). When evaluating these alternatives, procurement directors must consider not only product quality and regulatory compliance but also geographic diversity to reduce geopolitical and logistical vulnerabilities. Qualification timelines for new suppliers can range from several months to over a year, depending on the complexity of the product and the regulatory requirements. Therefore, initiating these processes promptly is essential. Regulatory affairs heads should prioritize due diligence on the quality management systems and regulatory history of any prospective alternative supplier to prevent similar compliance issues from arising in the future.
AvKARE's History of Regulatory Non-Compliance: A Pattern of Risk
This latest recall for a label mix-up is not an isolated incident for AvKARE; it fits into a concerning pattern of regulatory non-compliance that spans several years. Our intelligence highlights multiple prior recalls, indicating systemic issues within the company's quality management system. In January 2020, AvKARE initiated a recall for Dutasteride due to impurity failures, exposing critical vulnerabilities in their manufacturing processes. This was followed by a Lamotrigine recall in June 2020, attributed to foreign substance contamination, further underscoring deficiencies in their quality control. The most significant prior event, highly relevant to the current situation, was a Class I recall in December 2020 for a Trazodone-Sildenafil mix-up at a third-party facility. This previous mix-up, a high-severity event, directly parallels the current labeling error, suggesting a persistent challenge with product segregation and labeling integrity across their supply chain, whether internal or external. More recently, in December 2024, AvKARE initiated a Class II recall of Cinacalcet Tablets over nitrosamine impurity concerns. This recurring history of impurity issues, contamination, and critical mix-ups signals a high-risk profile for AvKARE. For regulatory affairs and procurement, this pattern demands heightened scrutiny of all AvKARE products and robust supplier qualification protocols.
Remediation Expectations and Heightened Regulatory Scrutiny
As this recall of Carboxymethylcellulose Sodium Ophthalmic Solution is currently ongoing, AvKARE is expected to implement immediate and comprehensive corrective and preventive actions (CAPA) to address the root cause of the label mix-up. The FDA will require a detailed investigation into how the mislabeling occurred, what controls failed, and what systemic changes will be put in place to prevent recurrence. This includes reviewing labeling procedures, quality assurance checks, and personnel training at their Pulaski, TN facility and any associated third-party logistics or packaging partners. Given AvKARE's extensive history of regulatory issues, including multiple recalls for impurities, contamination, and prior mix-ups, the company will undoubtedly face heightened scrutiny from the FDA. Future inspections are highly probable, and the agency will likely assess the effectiveness of AvKARE's CAPA plans with a critical eye. For regulatory affairs professionals, this means closely monitoring AvKARE's public statements and regulatory filings for updates on their remediation efforts. Supply chain VPs should prepare for potential extended disruptions or even further regulatory actions if AvKARE fails to demonstrate sustained compliance, impacting the long-term viability of sourcing from this supplier.